Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 397,089
  • Shares Outstanding, K 218,181
  • Annual Sales, $ 194,620 K
  • Annual Income, $ -51,930 K
  • EBIT $ -35 M
  • EBITDA $ 2 M
  • 60-Month Beta 0.74
  • Price/Sales 2.01
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 87.09% ( -11.97%)
  • Historical Volatility 70.21%
  • IV Percentile 29%
  • IV Rank 19.15%
  • IV High 328.98% on 11/27/23
  • IV Low 29.81% on 08/21/24
  • Put/Call Vol Ratio 0.45
  • Today's Volume 324
  • Volume Avg (30-Day) 963
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 17,636
  • Open Int (30-Day) 18,949

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5400 +18.83%
on 10/23/24
2.0200 -9.41%
on 11/11/24
+0.1900 (+11.59%)
since 10/22/24
3-Month
1.2400 +47.58%
on 10/01/24
2.0200 -9.41%
on 11/11/24
+0.3600 (+24.49%)
since 08/22/24
52-Week
0.8000 +128.75%
on 06/26/24
2.4800 -26.21%
on 03/28/24
+0.8400 (+84.85%)
since 11/22/23

Most Recent Stories

More News
New Strong Sell Stocks for November 22nd

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:ATI Inc. ATI is a specialty manufacturing company. The Zacks Consensus Estimate for its current year earnings has been revised...

ALTG : 7.67 (+2.13%)
ATI : 60.07 (+3.28%)
AKBA : 1.8350 (+0.82%)
Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics: Q3 Earnings Snapshot

AKBA : 1.8350 (+0.82%)
Talis: Q2 Earnings Snapshot

Talis: Q2 Earnings Snapshot

AKBA : 1.8350 (+0.82%)
Akebia Therapeutics: Q2 Earnings Snapshot

Akebia Therapeutics: Q2 Earnings Snapshot

AKBA : 1.8350 (+0.82%)
Akebia Therapeutics: Q1 Earnings Snapshot

Akebia Therapeutics: Q1 Earnings Snapshot

AKBA : 1.8350 (+0.82%)
Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics: Q3 Earnings Snapshot

AKBA : 1.8350 (+0.82%)
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8350 (+0.82%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8350 (+0.82%)
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8350 (+0.82%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.8350 (+0.82%)

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 1.9300
2nd Resistance Point 1.8800
1st Resistance Point 1.8500
Last Price 1.8350
1st Support Level 1.7700
2nd Support Level 1.7200
3rd Support Level 1.6900

See More

52-Week High 2.4800
Fibonacci 61.8% 1.8382
Last Price 1.8350
Fibonacci 50% 1.6400
Fibonacci 38.2% 1.4418
52-Week Low 0.8000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar